Sonia Rodriguez-Novoa

Summary

Publications

  1. doi request reprint Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS 22:2535-7. 2008
  2. doi request reprint Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701
    Sonia Rodriguez-Novoa
    Pharmacology and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:1567-9. 2010
  3. ncbi request reprint [The pharmacogenetics of response to antiretroviral therapy]
    Sonia Rodriguez-Novoa
    Unidad de Farmacología Clínica, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:10-7. 2008
  4. doi request reprint Current trends in screening across ethnicities for hypersensitivity to abacavir
    Sonia Rodriguez-Novoa
    Department of Pharmacokinetics and Pharmacogenomics, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Pharmacogenomics 9:1531-41. 2008
  5. doi request reprint Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study
    Sonia Rodriguez-Novoa
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 48:e108-16. 2009
  6. doi request reprint Pharmacogenetics of tenofovir treatment
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Department of Infectious Diseases, Hospital Carlos III, C Sinesio Delgado n o 10, CP 28029 Madrid, Spain
    Pharmacogenomics 10:1675-85. 2009
  7. doi request reprint Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection
    Judit Morello
    Laboratory of Pharmacology, Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 202:1185-91. 2010
  8. ncbi request reprint Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:429-37. 2008
  9. doi request reprint Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 24:821-5. 2008
  10. doi request reprint Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy
    Judit Morello
    Laboratory of Molecular Biology, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 27:1043-5. 2011

Collaborators

Detail Information

Publications44

  1. doi request reprint Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS 22:2535-7. 2008
    ..A substantial proportion of patients under atazanavir-therapy experienced significant hyperbilirubinemia and jaundice following initiation of hepatitis-C therapy...
  2. doi request reprint Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701
    Sonia Rodriguez-Novoa
    Pharmacology and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:1567-9. 2010
    ..To study the correlation between the HLA-B*5701 allele and the single nucleotide polymorphism in HCP5 (rs2395029)...
  3. ncbi request reprint [The pharmacogenetics of response to antiretroviral therapy]
    Sonia Rodriguez-Novoa
    Unidad de Farmacología Clínica, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:10-7. 2008
    ..Some host factors also influence antiviral response, such as interleukins and major histocompatibility complex. The present article analyzes the most important genetic markers associated with antiretroviral treatment response...
  4. doi request reprint Current trends in screening across ethnicities for hypersensitivity to abacavir
    Sonia Rodriguez-Novoa
    Department of Pharmacokinetics and Pharmacogenomics, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Pharmacogenomics 9:1531-41. 2008
    ..The heterogeneity in the prevalence of HLA-B*5701 across distinct ethnicities accounts for differences in the risk of abacavir hypersensitivity reactions in distinct populations...
  5. doi request reprint Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study
    Sonia Rodriguez-Novoa
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 48:e108-16. 2009
    ..Although rare, the mechanism by which tenofovir causes renal damage is not well characterized. We have explored the association between kidney tubular dysfunction (KTD) and polymorphisms in genes encoding drug transporters...
  6. doi request reprint Pharmacogenetics of tenofovir treatment
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Department of Infectious Diseases, Hospital Carlos III, C Sinesio Delgado n o 10, CP 28029 Madrid, Spain
    Pharmacogenomics 10:1675-85. 2009
    ..In this review, all relevant pharmacogenetic factors that may play a role in the risk of renal toxicity associated with the use of tenofovir are summarized...
  7. doi request reprint Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection
    Judit Morello
    Laboratory of Pharmacology, Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 202:1185-91. 2010
    ....
  8. ncbi request reprint Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:429-37. 2008
    ..There is little information about the influence of antiretroviral drugs on the antiviral activity of pegylated interferon (PEG-IFN) plus ribavirin (RBV) against hepatitis C virus (HCV)...
  9. doi request reprint Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 24:821-5. 2008
    ..Patients with complete viral suppression under ATV/r 300/100 mg qd may benefit from switching to ATV 400 mg qd guided by TDM, which may make it possible to minimize adverse events without compromising antiviral efficacy in most cases...
  10. doi request reprint Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy
    Judit Morello
    Laboratory of Molecular Biology, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 27:1043-5. 2011
    ..9). Total bilirubin, a nonexpensive, simple, and widely available parameter, might be used as a surrogate of virological response to ATV-based regimens, especially in areas with limited resources where HIV-RNA testing is not available...
  11. doi request reprint Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 11:197-204. 2010
    ..Raltegravir has demonstrated good antiviral activity and safety profile in twice-daily (bid) dosing. However, its long terminal elimination half-life might allow once-daily (qd) administration...
  12. doi request reprint Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir
    Pablo Labarga
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS 23:689-96. 2009
    ..Kidney abnormalities are the main concern using the drug. As glomerular function is infrequently affected in patients treated with TDF, herein, we report the results of an extensive examination of tubular function...
  13. doi request reprint Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse
    Pablo Labarga
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    J Acquir Immune Defic Syndr 53:364-8. 2010
    ....
  14. pmc Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C
    Judit Morello
    Laboratory of Pharmacology, Hospital Carlos III, 28029 Madrid, Spain
    Antimicrob Agents Chemother 54:1647-9. 2010
    ..5 microg/ml (4.5 [1.3 to 15.5]), baseline serum HCV RNA (2.5 [1.2 to 5.1]), and HCV genotype 1 or 4 (13.3 [2.6 to 66.7]). Monitoring of RBV C(trough) may permit early adjustment of RBV dosage to avoid HCV relapse...
  15. ncbi request reprint Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS 21:41-6. 2007
    ..Polymorphisms at the uridin-glucoronosyl-transferase 1A1 (UGT1A1) and multidrug resistance 1 (MDR1) genes may influence, respectively, bilirubin and ATV plasma concentrations...
  16. ncbi request reprint Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 195:973-9. 2007
    ..Most antiretrovirals are metabolized in the liver, and lower dosing could be advisable in patients with severe liver insufficiency...
  17. ncbi request reprint Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 21:583-8. 2007
    ..Information on the impact of therapy with pegylated interferon (pegIFN) plus ribavirin on mtDNA is scarce and conflicting results have been reported...
  18. ncbi request reprint Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir
    Teresa Garcia-Benayas
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:333-7. 2006
    ..These results add a further note of caution to the use of TDF and ddI in combination...
  19. doi request reprint The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring
    Judit Morello
    Pharmacokinetic Unit, Hospital Carlos III, Madrid, Spain
    Ther Drug Monit 32:242-4. 2010
    ..Fasting triglycerides were also reduced in 2 of them. Plasma HIV-RNA remained undetectable in all patients, despite the observed decline in TPV trough concentrations...
  20. ncbi request reprint Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 61:200-5. 2008
    ..If proved, this strategy could be particularly attractive for the subset of patients with greater cardiovascular risk...
  21. doi request reprint Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 26:419-24. 2010
    ..Extensive intraerythrocyte accumulation of RBV following boosted production of red blood cells by EPO could explain these findings...
  22. ncbi request reprint Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, C Sinesio Delgado 10, 28029 Madrid, Spain
    Expert Opin Pharmacother 8:839-50. 2007
    ..TPV use is associated with an excess of grade 3/4 liver enzyme elevations compared with other ritonavir-boosted PIs, and the potential for drug-drug interactions is relevant and must be considered when prescribing TPV...
  23. ncbi request reprint Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:511-7. 2008
    ..Differences between PEG-IFN-alpha molecules could be more pronounced in HIV-coinfected individuals, in whom response to HCV treatment is impaired...
  24. doi request reprint Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 23:1374-6. 2007
    ..We tested HLA-B*5701 in 53 Spaniards infected with HIV who received ABC treatment. The presence of HLA-B5701 had strong positive and negative predictive values for ABC HSR, 92% and 63%, respectively...
  25. pmc Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients
    Judit Morello
    Pharmacology Unit, Hospital Carlos III, Madrid, Spain
    Antimicrob Agents Chemother 53:4153-8. 2009
    ..48 for TPV C(trough). HIV-infected patients who initiate a salvage regimen based on TPV may benefit from baseline drug resistance testing and TPV plasma concentration determination, as vIQ is the best predictor of a virological response...
  26. ncbi request reprint Combinations of nucleoside/nucleotide analogues for HIV therapy
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Rev 6:234-43. 2004
    ..Interferences between the pathways involved into the intracellular activation of some nucleoside/nucleotide analogues may help to understand why certain drug combinations should be avoided...
  27. doi request reprint Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C
    Eugenia Vispo
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:543-7. 2010
    ..Herein, we report the hepatic safety profile of raltegravir in a relatively large group of HIV/HCV co-infected patients, a population that was poorly represented in the registrational studies...
  28. doi request reprint Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients
    Pablo Labarga
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 24:777-9. 2010
    ..In all instances, viral rebound occurred after 12 weeks of therapy. These results do not support an increased risk of early virological failure using TDF/FTC/NVP...
  29. doi request reprint Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse
    Pablo Labarga
    Hospital Carlos III, Madrid, Spain
    AIDS 25:1131-3. 2011
    ..1 (2.7-90.9)], prior relapse [9.6 (1.5-62.4)] and ribavirin plasma trough concentrations at week 4 [4.9 (1.3-18.4)]. IL28B-CC only predicted response in prior nonresponders carrying HCV genotypes 1/4 [25.1 (1.9-337)]...
  30. doi request reprint Association between tipranavir plasma levels and virological response in HIV-infected patients
    Judit Morello
    Hospital Carlos III, Madrid 28029, Spain
    AIDS Res Hum Retroviruses 24:389-91. 2008
    ..8 vs. 13.8 g/ml, p = 0.017). Thus, therapeutic drug monitoring might be helpful in ensuring a viral response in this subset of patients...
  31. ncbi request reprint Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
    Sonia Rodriguez-Novoa
    Pharmacokinetic Unit, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 40:1358-61. 2005
    ..Conversely, 20% of subjects with the wild-type genotype had subtherapeutic concentrations of EFV. CYP2B6-516 genotyping may help to identify subjects who have plasma EFV concentrations that are outside of the therapeutic range...
  32. doi request reprint Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations
    Carolina Garrido
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 28:156-64. 2012
    ..001). Undetectable RAL C(t) was seen only in patients failing RAL without integrase resistance mutations (64.1% of them). RAL failures in the absence of integrase resistance mutations mainly reflect poor drug compliance...
  33. doi request reprint Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C
    Norma I Rallon
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 53:1291-5. 2011
    ..Anemia developed in 80% of patients with normal ITPA activity compared with 33% of those with reduced ITPA activity. In contrast, ITPA variants did not influence sustained virological response...
  34. doi request reprint Renal toxicity associated with tenofovir use
    Sonia Rodriguez-Novoa
    Hospital Carlos III, Pharmacokinetic and Pharmacogenetic Unit, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Drug Saf 9:545-59. 2010
    ..Despite its proven efficacy and safety, cases of kidney tubular dysfunction have increasingly been reported and concern exists about the risk of nephrotoxicity associated with the long-term use of TFV...
  35. ncbi request reprint Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C
    Judit Morello
    Services of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Ther Drug Monit 29:802-6. 2007
    ..The clinical interest of this assay was evaluated in a subset of patients under RBV therapy. Mean RBV plasma concentrations at steady state were higher in responders compared with nonresponders (3-3.2 mug/mL versus 2.2-2.3 microg/mL)...
  36. ncbi request reprint Pharmacogenetics in HIV therapy
    Sonia Rodriguez-Novoa
    Pharmacokinetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS Rev 7:103-12. 2005
    ..Herein, we review the genetic polymorphisms known to be associated with altered pharmacokinetics of antiretrovirals, which may influence the efficacy and toxicity of these drugs...
  37. doi request reprint Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients
    Inmaculada Jimenez-Nacher
    Hospital Carlos III, Service of Pharmacy, Madrid, Spain
    Expert Opin Drug Metab Toxicol 7:457-77. 2011
    ..Treatment of co-morbidities has become a difficult task in HIV-infected individuals because pharmacokinetic and/or pharmacodynamic interactions are common when other medications are prescribed along with antiretroviral agents...
  38. doi request reprint Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations
    Sonia Rodriguez-Novoa
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 24:1064-6. 2010
    ..Median TFV plasma trough concentration was higher in patients with KTD than in the rest (182 vs. 106 ng/ml; P = 0.001). This dose-dependent effect further supports an involvement of TFV in KTD...
  39. ncbi request reprint Atazanavir: the advent of a new generation of more convenient protease inhibitors
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 6:50-61. 2005
    ..Recent clinical studies support the assertion that atazanavir may display excellent behavior as part of first-line regimens in rescue interventions or in simplification strategies...
  40. ncbi request reprint Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study
    Matilde Sanchez-Conde
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 23:1237-41. 2007
    ..Its efficacy does not seem to be compromised when ddI is administered with food. Therefore, this regimen merits further investigation in larger comparative trials...
  41. doi request reprint Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements
    Inmaculada Jimenez-Nacher
    Service of Pharmacy, Pharmacokinetics and Pharmacogenetics, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    J Antimicrob Chemother 62:816-22. 2008
    ..The choice of antiretroviral drugs has evolved over the last decade. Recognition of trends and determinants of changes may help to make predictions on prescription patterns...
  42. ncbi request reprint Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities
    Judit Morello
    Department of Pharmacy, Hospital Carlos III, Madrid, Spain
    Drug Metab Lett 3:67-9. 2009
    ..Triglycerides and total/HDL-cholesterol ratio were significantly lower with tablets than with capsules. Lopinavir concentrations were higher with tablets than with capsules...
  43. doi request reprint Noncirrhotic portal hypertension in HIV infection
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Curr Opin Infect Dis 24:12-8. 2011
    ..the cause of liver abnormalities remains unknown for a subset of patients, some of whom present with noncirrhotic portal hypertension (NCPH)...
  44. doi request reprint Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C
    Judit Morello
    Pharmacy Unit, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 62:1174-80. 2008
    ..Herein, we review the relationship between ribavirin plasma concentrations and both virological response and toxicity, in order to define an optimal therapeutic range for ribavirin...